Alpha 2.0
Login Register
» Articles » PMID: 7000243

Atenolol, Sustained-release Oxprenolol, and Long-acting Propranolol in Hypertension

Overview
Journal Br Med J
Specialty General Medicine
Date 1980 Jun 28
PMID 7000243
Citations 24
Authors
J C Petrie
T A Jeffers
O J Robb
A K Scott
J Webster
Affiliations
Soon will be listed here.
Abstract

The effect of once-daily atenolol, sustained-release oxprenolol (a new formulation of oxprenolol presented as a compressed tablet in a waxed matrix), and long-acting propranolol (a new formulation presented as spheriods in a capsule) was studied in a double-blind crossover trial in 23 carefully selected hypertensive outpatients. After a run-in period with matching placebo each patient received atenolol (100 mg/day), sustained-release oxprenolol (160 mg/day), long-acting propranolol (160 mg/day), and placebo according to a randomised sequence. After four weeks' treatment with sustained-release oxprenolol blood pressure in the two to four hours before the next dose was not significantly lower than after placebo. The effectiveness of atenolol and of the new formulation of propranolol in reducing blood pressure was confirmed. These results suggest that the present formulation of sustained-release oxprenolol should be reconsidered.

Citing Articles

Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.

Wong G, Boyda H, Wright J Cochrane Database Syst Rev. 2016; 3:CD007451.

PMID: 26961574 PMC: 6486283. DOI: 10.1002/14651858.CD007451.pub2.

Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension.

Wong G, Wright J Cochrane Database Syst Rev. 2014; (2):CD007452.

PMID: 24585007 PMC: 10603273. DOI: 10.1002/14651858.CD007452.pub2.

Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Nicholls D, Harron D, Mcainsh J, Castle W, Barker N, Shanks R Br J Clin Pharmacol. 1982; 14(5):727-32.

PMID: 7138752 PMC: 1427478. DOI: 10.1111/j.1365-2125.1982.tb04964.x.

Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

Freestone S, Silas J, Lennard M, Ramsay L Br J Clin Pharmacol. 1982; 14(5):713-8.

PMID: 7138751 PMC: 1427486. DOI: 10.1111/j.1365-2125.1982.tb04962.x.

Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.

Floras J, Jones J, Hassan M, Sleight P Br Med J (Clin Res Ed). 1982; 285(6352):1387-92.

PMID: 6814568 PMC: 1500409. DOI: 10.1136/bmj.285.6352.1387.

References
1.
Petrie J, Galloway D, Webster J, SIMPSON W, Lewis J . Atenolol and bendrofluazide in hypertension. Br Med J. 1975; 4(5989):133-5. PMC: 1674832. DOI: 10.1136/bmj.4.5989.133. View
2.
SPEARS G . Experience with a slow-release formulation of oxprenolol. N Z Med J. 1978; 87(609):245-6. View
3.
Jeffers T, Webster J, Reid B, Petrie J, Barker N . Atenolol and metoprolol in mild hypertension. Br Med J. 1978; 2(6147):1269. PMC: 1608517. DOI: 10.1136/bmj.2.6147.1269. View
4.
Bobik A, Jennings G, Korner P, Ashley P, Jackman G . Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Br J Clin Pharmacol. 1979; 7(6):545-9. PMC: 1429662. DOI: 10.1111/j.1365-2125.1979.tb04640.x. View
5.
Jones D, Daniel J, Hamilton C, Reid J . Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol. Br J Clin Pharmacol. 1980; 9(1):27-31. PMC: 1429915. DOI: 10.1111/j.1365-2125.1980.tb04792.x. View